The DF/HCC Breast Users Committee and Resources for Research

Composition: The Breast Users Committee is the supervising body for use of the breast cancer data and/or specimens from the DF/HCC. The Users Committee will be composed of at least one member from each participating organization which includes Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, and Massachusetts General Hospital, representing the disciplines of pathology, surgery, and medical oncology, radiation oncology and biostatistics. Members will be appointed by the chairs with no pre-specified term limits. The current membership is presented below.

DF/HCC Breast Users Committee Members

Co-chairs

Nancy Lin, MD; DFCI
Deborah Dillon, MD; BWH
Laura Collins, MD; BIDMC

USERS COMMITTEE MEMBERS

Jennifer Bellon, MD; BWH
Leif Ellisen, MD PhD; MGH
Rachel Freedman, MD, DFCI
Judy Garber, MD, MPH; DFCI
Steven Isakoff, MD, PhD; MGH
Rinath Jeselsohn, MD, PhD
Tari King, MD; BWH
Filipa Lynce, MD
Erica Mayer, MD, MPH
Beth Mittendorf, MD, PhD; BWH
Beverly Moy, MD; MGH
Heather Parsons, MD, MPH
Ann Partridge, MD, MPH
Stuart Schnitt, MD; BIDMC
Dennis C. Sgroi, MD; MGH
Nabihah Tayob, PhD, DFCI
Sara Tolaney, MD; DFCI
Nadine Tung, MD; BIDMC
Jean Zhao, PhD; DFCI

Proposals Involving Use of Oncomap/Oncopanel Data:

A smaller subset of the DFHCC Breast Users Committee will review all proposals involving use of Oncomap and/or Oncopanel data in breast cancer patients.

This committee is structured as follows:

Co-chairs:

Nancy Lin, MD
Deborah Dillon, MD

Members:

Tari King, MD
Erica Mayer, MD, MPH
Heather Parsons, MD, MPH

Ad-hoc Members:

Jennifer Bellon, MD (as needed for proposals involving local therapy questions)
Judy Garber, MD, MPH (as needed for germline genetics expertise)

Proposals Involving Qualitative and Survey Studies:

A smaller subset of DFHCC Breast Users Committee will review all proposals involving the use of qualitative and survey study in breast cancer patients. The committee will review for the validity and feasibility of such studies within our department and clinic and ensure that there is coordination and no redundancy from the perspective of our patients.

This committee is structured as follows:

Chair:

Rachel Freedman, MD, MPH

Members:

Tari King, MD
Ann Partridge, MD, MPH
Nancy Lin, MD
Christine J. McLaughlin

Ad-hoc Members:

Jennifer Bellon, MD (as needed for proposals involving local therapy questions)
Judy Garber, MD, MPH (as needed for germline genetics expertise)
Michael Hassett, MD, MPH
Sara Tolaney, MD, MPH

Hide

Purpose: The members of the DF/HCC Breast Users Committee are charged with reviewing the feasibility and scientific validity of proposed clinical and health services research, qualitative improvement (QI) projects, and translational and laboratory-based projects using the specimens and clinical data available through DF/HCC breast cancer-focused research protocols. The committee also recommends a review ofqualitative studies and surveys being implemented within DF/HCC as it relates to breast cancer that will require the use DF/HCC investigator platforms (e.g., if a researcher needs to use existing datasets to identify and contact patients).

Scope: All research using clinical data and/or biospecimens from breast cancer patients treated at any of the participating institutions must be reviewed by the Users Committee and is subject to a required annual renewal process for ongoing projects. Generally exempt from this scope are studies that are pre-specified in prospective therapeutic clinical trials or which include IRB-approved amendments to existing protocols by the primary research team for that database or specimen bank. For example, use of archival tissue specimens for the purpose of assessing a pre-specified biomarker to determine eligibility into an IRB-approved clinical trial does not require additional Users Committee approval to proceed. In contrast, secondary use of clinical data and/or biospecimens from clinical trials not explicitly specified in the original IRB-approved protocol is subject to Users Committee review.